MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:38Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antiarrhythmics]]
			[[Category:Cardiovascular agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #218

2026-05-23T04:00:16Z

parser-claude batch MedTemplate pre-fill, Top 300 #218

New page

{{MedTemplate
| generic = Amiodarone
| brand = Cordarone, Pacerone, Nexterone (IV)
| structure =
| classes = [[:Category:Antiarrhythmics|Antiarrhythmic (Vaughan-Williams class III)]], [[:Category:Cardiovascular_agents|Cardiovascular agent]]
| uses = <vote slug="vf-vt-cardiac-arrest-use">Recurrent ventricular fibrillation or hemodynamically unstable VT</vote>, <vote slug="afib-rhythm-control-use">Atrial fibrillation rhythm control (when structural heart disease limits other options)</vote>, <vote slug="vt-storm-use">Electrical storm / VT storm</vote>
| starting_dose = Oral load 800-1600 mg/d in divided doses for 1-3 weeks, then 600-800 mg/d for 1 month, then 200-400 mg/d maintenance; IV 150 mg over 10 min then 1 mg/min for 6 hours then 0.5 mg/min
| preparations = 100, 200, 400 mg tablets; 50 mg/mL IV (with polysorbate 80 in older formulations causing hypotension); 1.5 mg/mL Nexterone IV (PVC-free, lower hypotension risk)
| fda_max = Oral maintenance 400 mg/d typical; higher in refractory cases
| pill_id =
| routes = Oral, IV
| onset = IV: minutes; oral: weeks to load
| duration = Weeks after discontinuation (extremely long half-life)
| halflife = ~58 days (parent); ~61 days (desethylamiodarone, active metabolite)<ref name="cordarone-label">FDA Prescribing Information, Cordarone (amiodarone HCl), Wyeth/Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018972s055lbl.pdf</ref>
| bioavailability = ~50% (oral; highly variable)<ref name="cordarone-label" />
| pregnancy = Generally avoided; fetal goiter/hypothyroidism risk (iodine load). Used only for life-threatening arrhythmia.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries '''Boxed Warnings''' for pulmonary toxicity (interstitial pneumonitis, fibrosis), hepatotoxicity, and proarrhythmia<ref name="cordarone-label" />
| mechanism = <vote slug="amiodarone-mech-claim">Amiodarone is a multi-class antiarrhythmic with primary class III (K+ channel blocker, prolongs action potential and refractoriness) action plus class I (Na+ channel blocker), class II (β-adrenergic antagonist), and class IV (Ca²⁺ channel blocker) effects.</vote> Heavily iodinated (37% iodine by weight); cumulative tissue burden underlies the constellation of organ toxicities: pulmonary fibrosis, thyroid (hyper- or hypothyroidism), hepatic, corneal microdeposits, blue-gray skin discoloration (slate-blue, especially sun-exposed), peripheral neuropathy, optic neuropathy. Routine monitoring: TSH, LFTs, CXR/PFTs, ECG (QT). Numerous drug interactions via CYP3A4, CYP2C9, and P-gp inhibition<ref name="cordarone-label" />.
}}

== References ==
<references />

Amiodarone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #218